Peanut threat: oral immunotherapy has its limitations

Stopping therapy risks recurrence of allergic reactions, long-term study finds

Oral immunotherapy for peanut allergy can successfully desensitise patients to high doses of peanut protein, but the protection rapidly declines once treatment stops, a US study has found.


The findings are consistent with a recent systematic review and meta-analysis of peanut allergy oral immunotherapy trials, which found the experimental treatment increased the risk of life-threatening anaphylactic reactions without improving quality of life.

In the Stanford University-run phase two study, 120 patients with peanut allergy aged 7-55 (median